Emergent BioSolutions announced that the U.S. Food and Drug Administration approved its supplemental New Drug Application for 6‑count and 24‑count multipack configurations of its over‑the‑counter NARCAN® Nasal Spray on February 12, 2026. The new packaging options will be available through the company’s NARCANDirect® ordering platform, allowing partners to distribute larger volumes of naloxone to community programs and high‑volume sites.
Since its 2016 launch, more than 85 million doses of NARCAN® have been distributed across the United States and Canada. The approval makes Emergent the first company to offer an OTC naloxone product in multipack form, positioning it to capture a projected $1.5 billion market that is expected to double by 2030. The first‑mover advantage is expected to translate into pricing power and increased market share against competitors such as Pfizer’s prescription‑only generic and Viatris’ injectable naloxone.
Emergent’s strategy to broaden access to life‑saving opioid overdose treatment is reinforced by the multipack approval. By enabling bulk distribution, the company can better serve partners that manage large‑scale overdose response programs, thereby expanding its commercial reach and reinforcing its leadership in the naloxone market. The move also aligns with the company’s broader portfolio, which includes the KLOXXADO® nasal spray and other public‑health‑focused products.
Paul Williams, senior vice president of products business, said, “At Emergent, we work closely with our partners to develop solutions that help improve delivery, distribution and accessibility of NARCAN® Nasal Spray. The introduction of NARCAN® Nasal Spray multipacks marks a significant step in empowering our partners on the front lines. They can now better streamline bulk distribution, support broad preparedness efforts, and ultimately ensure that more communities and individuals have ready access to this life‑saving medication in the event of an opioid overdose emergency.”
The approval was well received by the market, with the company’s stock rising 1.94% in pre‑market trading on February 13. The positive reaction reflects investors’ recognition of the regulatory milestone’s potential to unlock new sales channels and strengthen Emergent’s competitive position. Analysts noted that the multipack launch could accelerate revenue growth and support the company’s guidance for the upcoming quarter.
Emergent’s Q3 2025 results showed revenue of $231.1 million and an adjusted gross margin of 61%, an expansion of 200 basis points year‑over‑year. The company has guided for Q4 2025 revenue of $216.5 million, indicating continued momentum. The multipack approval is expected to contribute to this trajectory by expanding distribution flexibility and tapping into the growing OTC naloxone market, thereby reinforcing the company’s financial outlook.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.